Literature DB >> 21370267

A new familial syndrome with dystonia and lower limb action myoclonus.

Justus Groen1, Anne-Fleur van Rootselaar, Sandra M A van der Salm, Bastiaan R Bloem, Marina Tijssen.   

Abstract

BACKGROUND: Myoclonus-dystonia (M-D) is genetic and clinically heterogeneous. Identification and description of rare M-D syndromes may contribute to gene identification.
RESULTS: Here, we describe a new, autosomal dominant M-D syndrome in a 3-generation pedigree showing anticipation. Patients have progressive action-induced multifocal dystonia and generalized myoclonus. A remarkable feature of the syndrome is action myoclonus in the lower extremities triggered by upright posture, causing instability. Electrophysiological characterization shows a 12-Hz peak in the EMG autospectrum and corticomuscular and intermuscular coherences.
CONCLUSIONS: A new familial M-D syndrome with progressive action myoclonus and dystonia is described.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21370267     DOI: 10.1002/mds.23557

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  2 in total

1.  CACNA1B mutation is linked to unique myoclonus-dystonia syndrome.

Authors:  Justus L Groen; Arturo Andrade; Katja Ritz; Hamid Jalalzadeh; Martin Haagmans; Ted E J Bradley; Aldo Jongejan; Dineke S Verbeek; Peter Nürnberg; Sylvia Denome; Raoul C M Hennekam; Diane Lipscombe; Frank Baas; Marina A J Tijssen
Journal:  Hum Mol Genet       Date:  2014-10-08       Impact factor: 6.150

2.  The CACNA1B R1389H variant is not associated with myoclonus-dystonia in a large European multicentric cohort.

Authors:  Niccolo E Mencacci; Léa R'bibo; Sara Bandres-Ciga; Miryam Carecchio; Giovanna Zorzi; Nardo Nardocci; Barbara Garavaglia; Amit Batla; Kailash P Bhatia; Alan M Pittman; John Hardy; Anne Weissbach; Christine Klein; Thomas Gasser; Ebba Lohmann; Nicholas W Wood
Journal:  Hum Mol Genet       Date:  2015-07-08       Impact factor: 6.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.